The FDA approved a drug this week that does something no oral antiviral has ever done.
The Moment That Changed
Picture this. Your patient’s spouse just tested positive for COVID-19. They feel fine. No symptoms. But they’ve been living under the same roof for the past 48 hours. They call you.
Until now, there wasn’t much to offer. Stay home. Mask up. Watch and wait. Almost half of household contacts end up getting infected and the clinical playbook for the exposed-but-not-yet-sick was essentially empty.
That changed on June 1st.
The FDA approved XOCOVA® (ensitrelvir) as the first and only oral medication to help prevent COVID-19 after exposure. Not treat it. Prevent it. That’s a different category of intervention entirely, and it opens a clinical window that belongs squarely in the pharmacist’s hands.
Why This Drug Is Different
XOCOVA works by inhibiting the enzyme the virus needs to replicate. Take it within 72 hours of a known exposure, and you can interrupt the virus before it gains enough of a foothold to cause illness.
In the pivotal Phase 3 trial (SCORPIO-PEP, published in the New England Journal of Medicine), that approach cut the risk of getting COVID-19 by 67%. Two out of three infections prevented. Among a study population where over 99% had been vaccinated, previously infected, or both; meaning this wasn’t a population with naive immune systems. The benefit was real and it was broad.
The drug is a simple 5-day regimen. Three tablets on day one, one tablet on days two through five. And unlike the COVID antiviral most pharmacists know best, XOCOVA doesn’t cause that metallic, bitter taste that has quietly driven Paxlovid non-adherence for years. In the PLATCOV head-to-head trial, only 1% of ensitrelvir patients reported dysgeusia, compared to 26% of those on nirmatrelvir–ritonavir and 1% in the no-treatment group; a dramatic improvement over Paxlovid’s well-known taste disturbance.
The Science Got Here the Hard Way
The approval story is worth knowing.
Before XOCOVA was a prevention drug, researchers tested it as a treatment. The SCORPIO-SR trial, published in JAMA Network Open, showed that patients treated within 72 hours recovered about a day faster than those on placebo and cleared the virus significantly more rapidly. Solid results. Enough to earn full approval in Japan.
Then came SCORPIO-HR… A bigger, more diverse global trial in higher-risk patients. That one didn’t meet its primary endpoint on symptom relief, even though the drug was still hammering the virus. Over 95% of treated patients had no detectable live virus by day 4, compared to 75% on placebo. The virus was being suppressed. But in a broader treatment population, that antiviral punch didn’t fully translate to faster symptom resolution.
That result didn’t kill the drug, it actually clarified where it works best. The antiviral effect was most powerful early, before symptoms escalated. Which pointed researchers toward exactly the right question: what if you used it before symptoms even began?
SCORPIO-PEP answered that. And the FDA approved XOCOVA on June 1st ahead of its scheduled review date.
How It Compares to Paxlovid
Healthcare professionals are going to get this question, so here’s a clean answer: Both drugs block the same enzyme. Both work. But they’re not the same drug, and they’re not approved for the same thing.
Paxlovid remains the gold standard for treatment. It has a strong evidence base for reducing hospitalization and death in high-risk patients with active COVID-19. XOCOVA is approved for prevention after exposure, a role Paxlovid was never designed for and doesn’t hold.
The practical differences: Paxlovid contains ritonavir as a pharmacokinetic booster, and that’s where the complexity lives. Ritonavir is a powerful CYP3A inhibitor so it significantly raises blood levels of dozens of co-administered drugs. Statins, tacrolimus, anticoagulants, antiarrhythmics, the interaction list is long, and it regularly disqualifies the patients who arguably need antiviral therapy most.
XOCOVA also inhibits CYP3A and is classified as a strong CYP3A inhibitor at its approved dose, meaning many of the same concomitant medications contraindicated with Paxlovid are also contraindicated with XOCOVA. However, the absence of ritonavir eliminates some additional interaction pathways, and the PLATCOV investigators noted that ensitrelvir inhibits CYP3A4 ‘albeit to a lesser extent than ritonavir.’ Some patients who cannot receive Paxlovid may still face similar restrictions with ensitrelvir, so the interaction profile should be carefully reviewed on a case-by-case basis.
The first head-to-head comparison (the PLATCOV trial, Lancet Infectious Diseases, 2025) found that ensitrelvir cleared the virus 82% faster than no treatment, and about 16% slower than Paxlovid. But far fewer patients on ensitrelvir reported dysgeusia, and viral rebound rates between the two drugs were statistically similar.
The short version: Paxlovid is more potent as a treatment. XOCOVA is the only approved option for prevention. For patients who can’t tolerate Paxlovid’s interactions, XOCOVA may be the answer in treatment settings too, though that indication hasn’t crossed the FDA finish line yet.
The 72-Hour Window Is the Whole Story
Here’s the thread that runs through every trial in the XOCOVA program: timing is the drug.
When patients got treated within 72 hours of symptom onset, the results were good. When they were treated later, in broader populations, the benefit shrank. When the drug was used in the window before symptoms, the postexposure window, the results were the best of all.
The lesson isn’t just pharmacological. It’s operational. A drug that should be started within 72 hours of the index patient’s symptom onset is only as effective as the speed at which patients can identify, access, and start it. That means patients need to know it exists before they’re in a household with someone who tests positive.
That’s a pharmacist conversation. It’s proactive counseling for your transplant patients, your elderly patients in assisted living, your caregivers managing high-risk family members. It’s a standing protocol for your long-term care accounts. It’s knowing, before the phone rings, what you’re going to say.
COVID-19 still resulted in an estimated 290,000 to 540,000 hospitalizations and 34,000 to 63,000 deaths in the U.S. in the twelve months before this approval and most of the people at greatest risk are already in your care. The window to help them is short. But it’s there.
Sources: Shionogi Press Release, June 1, 2026 | SCORPIO-PEP, NEJM 2026 | SCORPIO-SR, JAMA Network Open 2024 | SCORPIO-HR, Clinical Infectious Diseases 2025 | PLATCOV, Lancet Infectious Diseases 2025 | Paxlovid Prescribing Information
